Vera: Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study

 

• 72-week data consistent with disease modification in IgAN, selected as a best-ranked abstract;
• Rapid and sustained improvements in hematuria over 36 weeks, with resolution in significantly greater percentage of participants than placebo;

Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced data presentations from its Phase 2b ORIGIN trial of atacicept in immunoglobulin A nephropathy (IgAN), showing that atacicept stabilized kidney function through 72 weeks and led to rapid improvements in hematuria. These data were presented at the 61st European Renal Association Congress (ERA24) being held in Stockholm.

https://www.globenewswire.com/news-release/2024/05/25/2888237/0/en/Vera-Therapeutics-Presents-72-week-eGFR-Stabilization-and-Rapid-Hematuria-Improvement-in-Phase-2b-ORIGIN-Study-of-Atacicept-in-IgAN-at-the-61st-European-Renal-Association-Congress.html